18 With continued efforts in the development of newer antidiabetic agents, unimolecular GLP1R/GIPR dual agonists (twincretins) can provide added efficacy, especially among obese individuals with T2DM
The companys ability to scale effectively was also attributed to equipping specialized team members and delegating responsibilities rather than hoarding responsibilities and decision-making, as many founders struggle with
More receptor targets equals more neurological modulation equals higher likelihood of skin sensitivity
If well tolerated after three to four days, increase to one capsule twice daily before two main meals
The compounded versus brand-name question A critical distinction exists between compounded tirzepatide and FDA-approved Zepbound
As of May 2026, three pivotal readouts have been reported, with additional results expected through the remainder of 2026 [1][2][8][10]